AstraZeneca to supply certain doses of COVID therapy Evusheld to Switzerland - Reuters
Roland Magnusson/iStock Editorial via Getty Images                 

Switzerland is going to acquire about over 1.2K doses of AstraZeneca (NASDAQ:AZN) COVID-19 therapyÂ Evusheld (tixagevimab/cilgavimab), Reuters reported citing the country's government.
The drug is yet to be authorized and is currently under review, but may be used to treat patients while the process is ongoing, the report added.
This is second such agreement that Switzerland has undertaken to procure the therapy.
Evusheld has been shown to prevent and also treat COVID-19 in trials.